Nektar Therapeutics (NKTR) Downgraded to Hold at BidaskClub
BidaskClub downgraded shares of Nektar Therapeutics (NASDAQ:NKTR) from a buy rating to a hold rating in a research report sent to investors on Tuesday, September 18th.
Several other equities research analysts also recently weighed in on NKTR. ValuEngine downgraded shares of Nektar Therapeutics from a buy rating to a hold rating in a report on Tuesday, June 26th. Zacks Investment Research upgraded Nektar Therapeutics from a hold rating to a buy rating and set a $54.00 target price on the stock in a report on Monday, July 16th. HC Wainwright set a $54.00 price objective on Nektar Therapeutics and gave the stock a hold rating in a report on Friday, August 10th. TheStreet upgraded Nektar Therapeutics from a d rating to a c rating in a report on Wednesday, August 8th. Finally, William Blair restated a buy rating on shares of Nektar Therapeutics in a report on Monday, June 4th. Four analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The company has an average rating of Buy and a consensus target price of $82.91.
Shares of NASDAQ NKTR traded up $1.01 during trading on Tuesday, reaching $48.91. 2,001,546 shares of the stock were exchanged, compared to its average volume of 3,167,571. The stock has a market cap of $10.51 billion, a P/E ratio of -88.93 and a beta of 2.39. The company has a current ratio of 19.67, a quick ratio of 19.55 and a debt-to-equity ratio of 0.13. Nektar Therapeutics has a twelve month low of $22.75 and a twelve month high of $111.36.
In other Nektar Therapeutics news, Director Dennis L. Winger sold 30,000 shares of the stock in a transaction on Tuesday, August 21st. The stock was sold at an average price of $59.96, for a total transaction of $1,798,800.00. Following the completion of the transaction, the director now directly owns 57,750 shares in the company, valued at $3,462,690. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Dennis L. Winger sold 34,250 shares of the firm’s stock in a transaction on Tuesday, August 14th. The shares were sold at an average price of $60.60, for a total value of $2,075,550.00. Following the completion of the sale, the director now owns 59,875 shares of the company’s stock, valued at $3,628,425. The disclosure for this sale can be found here. Insiders have sold 96,000 shares of company stock valued at $5,825,680 over the last quarter. Corporate insiders own 4.31% of the company’s stock.
Hedge funds have recently made changes to their positions in the stock. Asset Management One Co. Ltd. bought a new position in Nektar Therapeutics during the first quarter worth about $110,000. We Are One Seven LLC bought a new position in Nektar Therapeutics during the first quarter worth about $118,000. Livforsakringsbolaget Skandia Omsesidigt bought a new position in Nektar Therapeutics during the second quarter worth about $137,000. Flagship Harbor Advisors LLC bought a new position in Nektar Therapeutics during the second quarter worth about $142,000. Finally, Raymond James Financial Services Advisors Inc. boosted its holdings in Nektar Therapeutics by 68.7% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 4,290 shares of the biopharmaceutical company’s stock worth $209,000 after buying an additional 1,747 shares during the last quarter. Hedge funds and other institutional investors own 92.20% of the company’s stock.
Nektar Therapeutics Company Profile
Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.
Read More: What is Compound Annual Growth Rate (CAGR)?
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.